Ultragenyx Pharmaceutical Company Profile (NASDAQ:RARE)

About Ultragenyx Pharmaceutical (NASDAQ:RARE)

Ultragenyx Pharmaceutical logoUltragenyx Pharmaceutical Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Its clinical-stage pipeline consists of two product categories: biologics (including a monoclonal antibody and an enzyme replacement therapy), and small-molecule substrate replacement therapies. Its product candidates under biologics category include KRN23 (UX023) and recombinant human beta-glucuronidase (rhGUS) (UX003). Its product candidates under small-molecule category include UX007 and aceneuramic acid extended-release (Ace-ER) (UX001). It is also developing recombinant human protective protein cathepsin-A (rhPPCA). KRN23 is a fully human monoclonal antibody. rhGUS is an intravenous (IV) enzyme replacement therapy. UX007 is a substrate replacement therapy. It is developing Ace-ER for the treatment of GNE myopathy. rhPPCA is in preclinical development.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:RARE
  • CUSIP: N/A
  • Web: www.ultragenyx.com
Capitalization:
  • Market Cap: $2.4 billion
  • Outstanding Shares: 42,458,000
Average Prices:
  • 50 Day Moving Avg: $64.40
  • 200 Day Moving Avg: $66.83
  • 52 Week Range: $51.67 - $91.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.56
  • P/E Growth: -0.17
Sales & Book Value:
  • Annual Revenue: $115,999.00
  • Price / Sales: 20,683.81
  • Book Value: $10.12 per share
  • Price / Book: 5.58
Profitability:
  • EBIDTA: ($280,320,000.00)
  • Return on Equity: -60.04%
  • Return on Assets: -52.85%
Debt:
  • Current Ratio: 6.70%
  • Quick Ratio: 6.70%
Misc:
  • Average Volume: 321,456 shs.
  • Beta: 1.89
  • Short Ratio: 21.74
 

Frequently Asked Questions for Ultragenyx Pharmaceutical (NASDAQ:RARE)

What is Ultragenyx Pharmaceutical's stock symbol?

Ultragenyx Pharmaceutical trades on the NASDAQ under the ticker symbol "RARE."

How were Ultragenyx Pharmaceutical's earnings last quarter?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) issued its earnings results on Thursday, July, 27th. The company reported ($1.72) earnings per share for the quarter, topping the Zacks' consensus estimate of ($1.73) by $0.01. During the same quarter in the prior year, the business posted ($1.46) EPS. View Ultragenyx Pharmaceutical's Earnings History.

When will Ultragenyx Pharmaceutical make its next earnings announcement?

Ultragenyx Pharmaceutical is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Ultragenyx Pharmaceutical.

Where is Ultragenyx Pharmaceutical's stock going? Where will Ultragenyx Pharmaceutical's stock price be in 2017?

16 equities research analysts have issued twelve-month target prices for Ultragenyx Pharmaceutical's shares. Their predictions range from $63.00 to $111.00. On average, they expect Ultragenyx Pharmaceutical's stock price to reach $84.47 in the next twelve months. View Analyst Ratings for Ultragenyx Pharmaceutical.

What are analysts saying about Ultragenyx Pharmaceutical stock?

Here are some recent quotes from research analysts about Ultragenyx Pharmaceutical stock:

  • 1. According to Zacks Investment Research, "Ultragenyx Pharmaceutical Inc. is involved in the identification, acquisition, development and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases. The Company's product pipeline include KRN23 (UX023) for the treatment of XLH, rhGUS (UX003) for the treatment of MPS 7, rhPPCA (UX004) for the treatment of galactosialidosis, Triheptanoin (UX007) for the treatment of LC-FAOD, Triheptanoin (UX007) for the treatment of Glut1 DS and SA-ER (UX001) for the treatment of HIBM which are in different clinical phases. Ultragenyx Pharmaceutical Inc. is headquartered in Novato, California. " (7/18/2017)
  • 2. Cowen and Company analysts commented, "We continue to see Pacira’s Exparel franchise as one of the most durable in specialty pharma and we believe that, over time, Exparel will continue to gain acceptance in the ortho community." (6/29/2017)
  • 3. Canaccord Genuity analysts commented, "INSM’s Ph3 Arikayce NTM CONVERT trial data is due ~September of this year." (5/8/2017)
  • 4. Jefferies Group LLC analysts commented, "uneventful" 2016 fourth quarter earnings call, as the company is expecting first commercial product by the end of 2017.Wang comments, "RARE 4Q16 EC was largely uneventful. Mgmt highlighted recent clinical progress in multiple programs and potentially first commercial product by YE17. We see overall favorable risk/reward heading into multiple data and regulatory catalysts in 2017, including KRN23 Ph3 data in adult XLH (1H17), BLA filing in the US, CHMP opinion in EU (2H17), Ace-ER Ph3 data in GNE myopathy (2H17)' RARE reported 4Q16 OpEx of $70.6M vs. our/consensus est of $74.8/69.9M. EPS was ($1.75) vs. our/consensus est of ($1.86/1.72). The company ended the quarter with $498.1M cash and guided that the cash should be sufficient to fund all clinical programs through Ph3 studies and potential launch. Mgmt guided to a continual increase in OpEx with a gradually slower YoY growth. Our $109 target is based on probability adjusted DCF. Risks include delay in EU conditional approval, less robust data, toxicity." (2/17/2017)

Who are some of Ultragenyx Pharmaceutical's key competitors?

Who are Ultragenyx Pharmaceutical's key executives?

Ultragenyx Pharmaceutical's management team includes the folowing people:

  • Daniel G. Welch, Independent Chairman of the Board
  • Emil D. Kakkis M.D. Ph.D., President, Chief Executive Officer, Director
  • Shalini Sharp, Chief Financial Officer, Executive Vice President
  • Sunil Agarwal M.D., President - Research and Development
  • Karah Parschauer, Executive Vice President, General Counsel
  • Jayson Dallas M.D., Chief Commercial Officer and Executive Vice President
  • Dennis Karl Huang, Chief Technical Operations Officer, Executive Vice President
  • Thomas Kassberg, Chief Business Officer, Executive Vice President
  • John R. Pinion II, Chief Quality Operations Officer and Executive Vice President Analytical Sciences and Research
  • William E. Aliski, Independent Director

Who owns Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical's stock is owned by a number of of retail and institutional investors. Top institutional investors include Capital Research Global Investors (12.21%), FMR LLC (8.96%), BlackRock Inc. (8.24%), Vanguard Group Inc. (7.37%), Capital International Investors (5.59%) and State Street Corp (3.62%). Company insiders that own Ultragenyx Pharmaceutical stock include Emil D Kakkis, Shalini Sharp, Sunil Agarwal, Theodore Alan Huizenga and William Aliski. View Institutional Ownership Trends for Ultragenyx Pharmaceutical.

Who sold Ultragenyx Pharmaceutical stock? Who is selling Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical's stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Wells Fargo & Company MN, Capital Guardian Trust Co., Bank of Montreal Can, JPMorgan Chase & Co., Jennison Associates LLC, Parametric Portfolio Associates LLC and TIAA CREF Investment Management LLC. Company insiders that have sold Ultragenyx Pharmaceutical stock in the last year include Emil D Kakkis, Shalini Sharp, Theodore Alan Huizenga and William Aliski. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

Who bought Ultragenyx Pharmaceutical stock? Who is buying Ultragenyx Pharmaceutical stock?

Ultragenyx Pharmaceutical's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Royal Bank of Canada, Capital International Investors, Pictet Asset Management Ltd., Vanguard Group Inc., First Trust Advisors LP and Alliancebernstein L.P.. View Insider Buying and Selling for Ultragenyx Pharmaceutical.

How do I buy Ultragenyx Pharmaceutical stock?

Shares of Ultragenyx Pharmaceutical can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ultragenyx Pharmaceutical's stock price today?

One share of Ultragenyx Pharmaceutical stock can currently be purchased for approximately $56.51.


MarketBeat Community Rating for Ultragenyx Pharmaceutical (NASDAQ RARE)
Community Ranking:  3.8 out of 5 (  )
Outperform Votes:  403 (Vote Outperform)
Underperform Votes:  130 (Vote Underperform)
Total Votes:  533
MarketBeat's community ratings are surveys of what our community members think about Ultragenyx Pharmaceutical and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 7 Hold Ratings, 8 Buy Ratings
Consensus Rating:Hold (Score: 2.44)
Consensus Price Target: $84.47 (49.47% upside)

Analysts' Ratings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
8/16/2017Evercore ISIInitiated CoverageIn -> In-Line$63.00HighView Rating Details
8/8/2017HC WainwrightReiterated RatingNeutral -> Neutral$72.00 -> $75.00LowView Rating Details
7/28/2017Canaccord GenuitySet Price TargetBuy$98.00LowView Rating Details
7/27/2017Sanford C. BernsteinInitiated CoverageMarket Perform$72.00HighView Rating Details
7/14/2017Jefferies Group LLCReiterated RatingHold$68.00HighView Rating Details
6/30/2017Stifel NicolausReiterated RatingBuy$111.00LowView Rating Details
6/29/2017Cowen and CompanyReiterated RatingOutperformLowView Rating Details
5/8/2017Morgan StanleyLower Price TargetEqual Weight$84.00 -> $79.00LowView Rating Details
4/19/2017Robert W. BairdReiterated RatingOutperform$90.00MediumView Rating Details
4/19/2017SunTrust Banks, Inc.Boost Price TargetBuy$100.00 -> $105.00MediumView Rating Details
4/19/2017WedbushDowngradeOutperform -> Neutral$80.00 -> $75.00HighView Rating Details
3/23/2017Piper Jaffray CompaniesReiterated RatingOverweight -> NeutralHighView Rating Details
11/30/2016Citigroup Inc.DowngradeNeutral -> SellN/AView Rating Details
11/14/2016Leerink SwannReiterated RatingOutperform$94.00 -> $90.00N/AView Rating Details
11/9/2016J P Morgan Chase & CoReiterated RatingBuy$106.00N/AView Rating Details
9/14/2016Credit Suisse GroupReiterated RatingBuy$101.00N/AView Rating Details
6/28/2016Bank of America CorporationInitiated CoverageBuy$72.00N/AView Rating Details
6/8/2016JMP SecuritiesReiterated RatingBuy$80.00 -> $84.00N/AView Rating Details
2/9/2016Sterne Agee CRTInitiated CoverageBuyN/AView Rating Details
8/31/2015Raymond James Financial, Inc.Initiated CoverageOutperform$125.00N/AView Rating Details
(Data available from 8/20/2015 forward)

Earnings

Earnings History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Earnings by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Earnings History by Quarter for Ultragenyx Pharmaceutical (NASDAQ RARE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($1.80)N/AView Earnings Details
7/27/2017Q2 2017($1.73)($1.72)$0.01 millionViewN/AView Earnings Details
5/4/2017Q1 2017($1.71)($1.63)$0.05 millionViewListenView Earnings Details
2/16/2017Q4 2016($1.72)($1.75)$0.05 million$0.01 millionViewN/AView Earnings Details
11/7/2016Q3($1.53)($1.64)$7.60 million$0.11 millionViewListenView Earnings Details
8/8/2016Q2($1.44)($1.46)$0.02 millionViewN/AView Earnings Details
5/9/2016Q1($1.29)($1.35)ViewN/AView Earnings Details
2/25/2016Q4($1.14)($1.42)ViewListenView Earnings Details
11/9/2015Q3($0.87)($1.03)ViewN/AView Earnings Details
8/13/2015Q215($0.63)($0.83)ViewListenView Earnings Details
5/11/2015Q1 15($0.54)($0.63)ViewListenView Earnings Details
3/25/2015Q414($0.53)($0.52)ViewListenView Earnings Details
11/10/2014Q314($0.46)($0.50)ViewN/AView Earnings Details
8/11/2014Q214($0.42)($0.45)ViewN/AView Earnings Details
5/12/2014Q114($0.37)($0.85)ViewN/AView Earnings Details
3/24/2014($0.38)($4.98)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)
2017 EPS Consensus Estimate: ($7.15)
2018 EPS Consensus Estimate: ($7.76)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174($1.82)($1.69)($1.75)
Q2 20174($1.93)($1.59)($1.76)
Q3 20174($2.01)($1.62)($1.81)
Q4 20174($2.09)($1.67)($1.83)
Q1 20181($1.99)($1.99)($1.99)
Q2 20181($1.97)($1.97)($1.97)
Q3 20181($1.91)($1.91)($1.91)
Q4 20181($1.89)($1.89)($1.89)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Insider Ownership Percentage: 9.20%
Institutional Ownership Percentage: 95.71%
Insider Trades by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Institutional Ownership by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Insider Trades by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/26/2017Theodore Alan HuizengaVPSell480$57.46$27,580.80View SEC Filing  
3/9/2017Theodore Alan HuizengaInsiderSell2,500$86.34$215,850.00View SEC Filing  
3/2/2017Shalini SharpCFOSell12,000$90.10$1,081,200.00View SEC Filing  
2/27/2017Shalini SharpCFOSell12,000$80.14$961,680.00View SEC Filing  
12/5/2016William AliskiDirectorSell6,000$78.19$469,140.00View SEC Filing  
11/9/2016Shalini SharpCFOSell24,000$71.20$1,708,800.00View SEC Filing  
10/19/2016Shalini SharpCFOSell12,000$61.40$736,800.00View SEC Filing  
10/14/2016Emil D KakkisCEOSell20,000$63.02$1,260,400.00View SEC Filing  
8/15/2016Emil D KakkisCEOSell20,000$67.61$1,352,200.00View SEC Filing  
7/21/2016Sunil AgarwalInsiderSell649$52.68$34,189.32View SEC Filing  
7/15/2016Emil D KakkisCEOSell20,000$50.85$1,017,000.00View SEC Filing  
6/20/2016Sunil AgarwalInsiderSell650$54.16$35,204.00View SEC Filing  
5/24/2016Sunil AgarwalInsiderSell650$66.00$42,900.00View SEC Filing  
5/16/2016Emil D KakkisCEOSell20,000$59.95$1,199,000.00View SEC Filing  
4/20/2016Sunil AgarwalInsiderSell649$70.53$45,773.97View SEC Filing  
4/15/2016Emil D KakkisCEOSell20,000$70.33$1,406,600.00View SEC Filing  
3/22/2016Sunil AgarwalInsiderSell650$61.45$39,942.50View SEC Filing  
2/22/2016Sunil AgarwalInsiderSell658$63.48$41,769.84View SEC Filing  
1/20/2016Sunil AgarwalinsiderSell585$72.83$42,605.55View SEC Filing  
12/31/2015Emil D. KakkisCEOSell20,000$114.52$2,290,400.00View SEC Filing  
12/22/2015Sunil AgarwalInsiderSell498$114.81$57,175.38View SEC Filing  
12/18/2015Theodore Alan HuizengainsiderSell1,500$110.55$165,825.00View SEC Filing  
8/20/2015Sunil AgarwalinsiderSell17,020$111.18$1,892,283.60View SEC Filing  
8/12/2015Thomas Richard KassbergSVPSell3,334$109.70$365,739.80View SEC Filing  
7/20/2015Shalini SharpCFOSell3,854$131.95$508,535.30View SEC Filing  
7/8/2015Thomas Richard KassbergSVPSell3,334$102.12$340,468.08View SEC Filing  
6/18/2015Shalini SharpCFOSell4,000$96.08$384,320.00View SEC Filing  
6/17/2015Theodore Alan HuizengaInsiderSell1,500$94.80$142,200.00View SEC Filing  
6/10/2015Thomas Richard KassbergSVPSell3,334$88.19$294,025.46View SEC Filing  
4/20/2015Shalini SharpCFOSell4,000$62.23$248,920.00View SEC Filing  
4/8/2015Thomas Richard KassbergSVPSell3,333$58.02$193,380.66View SEC Filing  
1/20/2015Shalini SharpCFOSell4,000$51.24$204,960.00View SEC Filing  
12/18/2014Shalini SharpCFOSell4,000$44.82$179,280.00View SEC Filing  
12/10/2014Thomas Richard KassbergSVPSell3,333$40.22$134,053.26View SEC Filing  
12/4/2014William AliskiDirectorSell6,000$42.16$252,960.00View SEC Filing  
11/20/2014Shalini SharpCFOSell4,000$44.07$176,280.00View SEC Filing  
11/12/2014Thomas Richard KassbergSVPSell3,333$41.85$139,486.05View SEC Filing  
10/8/2014Thomas Richard KassbergSVPSell3,333$53.26$177,515.58View SEC Filing  
9/18/2014Shalini SharpCFOSell4,000$56.00$224,000.00View SEC Filing  
9/10/2014Thomas Richard KassbergSVPSell3,333$54.82$182,715.06View SEC Filing  
9/3/2014Thomas Richard KassbergSVPSell20,000$53.91$1,078,200.00View SEC Filing  
8/18/2014Shalini SharpCFOSell4,000$53.97$215,880.00View SEC Filing  
7/14/2014Group Holdings (Sbs) Advis TpgInsiderSell488,820$37.60$18,379,632.00View SEC Filing  
1/31/2014Fmr LlcInsiderBuy175,000$21.00$3,675,000.00View SEC Filing  
1/30/2014Shalini SharpCFOBuy4,500$21.00$94,500.00View SEC Filing  
1/30/2014Thomas Richard KassbergSVPBuy1,500$21.00$31,500.00View SEC Filing  
1/30/2014William AliskiDirectorBuy5,000$21.00$105,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Latest Headlines for Ultragenyx Pharmaceutical (NASDAQ:RARE)
Source:
DateHeadline
finance.yahoo.com logoUltragenyx Pharmaceutical, Inc. – Value Analysis (NASDAQ:RARE) : August 17, 2017
finance.yahoo.com - August 17 at 7:13 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc. (RARE) Now Covered by Analysts at Evercore ISI
www.americanbankingnews.com - August 16 at 6:26 PM
finance.yahoo.com logoIHS Markit Score Update: Drop in demand for ETFs holding Ultragenyx Pharmaceutical Inc is a negative sign for its shares
finance.yahoo.com - August 11 at 7:57 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Expected to Post Quarterly Sales of $80,000.00
www.americanbankingnews.com - August 7 at 8:32 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 5 at 7:14 AM
finance.yahoo.com logoUltragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bearish Manner : RARE-US : August 3, 2017
finance.yahoo.com - August 4 at 7:23 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc. to Post FY2021 Earnings of $2.63 Per Share, SunTrust Banks Forecasts (RARE)
www.americanbankingnews.com - July 31 at 10:36 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given a $98.00 Price Target at Canaccord Genuity
www.americanbankingnews.com - July 28 at 2:08 PM
rttnews.com logoAGRX At FDA Altar Again, AZN Falls As MYSTIC Fails, VBIV Delivers A Good Shot
www.rttnews.com - July 28 at 7:12 AM
seekingalpha.com logoUltragenyx: An Interesting Company In The Rare Disease Space
seekingalpha.com - July 28 at 7:12 AM
finance.yahoo.com logoUltragenyx Reports Second Quarter 2017 Financial Results and Corporate Update
finance.yahoo.com - July 28 at 7:12 AM
finance.yahoo.com logoUltragenyx reports 2Q loss
finance.yahoo.com - July 28 at 7:12 AM
finance.yahoo.com logoEdited Transcript of RARE earnings conference call or presentation 27-Jul-17 9:00pm GMT
finance.yahoo.com - July 28 at 7:12 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Issues Quarterly Earnings Results
www.americanbankingnews.com - July 27 at 11:34 PM
seekingalpha.com logoUltragenyx More Than Meets The Eye? - Seeking Alpha
seekingalpha.com - July 26 at 6:41 AM
prnewswire.com logoGlobal Genes Announces RARE Champions of Hope Award Recipients to be Honored at 6th Annual RARE Tribute ... - PR Newswire (press release)
www.prnewswire.com - July 24 at 10:31 PM
seekingalpha.com logoUltragenyx Poised To Perform Well On Multiple Catalysts
seekingalpha.com - July 19 at 6:26 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc. (RARE) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - July 18 at 9:10 AM
nasdaq.com logoUltragenyx Pharmaceutical (RARE) Shares Cross Above 200 DMA - Nasdaq
www.nasdaq.com - July 18 at 7:45 AM
americanbankingnews.com logo$60,000.00 in Sales Expected for Ultragenyx Pharmaceutical Inc. (RARE) This Quarter
www.americanbankingnews.com - July 16 at 8:20 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given "Hold" Rating at Jefferies Group LLC
www.americanbankingnews.com - July 15 at 1:06 PM
americanbankingnews.com logoZacks: Analysts Anticipate Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Will Post Earnings of -$1.73 Per Share
www.americanbankingnews.com - July 14 at 4:34 PM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc. (RARE) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - July 11 at 8:58 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - July 11 at 7:24 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc. (NASDAQ:RARE) Rating Reiterated by Stifel Nicolaus
www.americanbankingnews.com - June 30 at 5:54 PM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc. (RARE) Earns Buy Rating from Cowen and Company
www.americanbankingnews.com - June 29 at 4:30 PM
streetinsider.com logoUltragenyx Pharma (RARE) Provides Regulatory Update on Burosumab Following Meeting with FDA
www.streetinsider.com - June 25 at 1:04 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc. (RARE) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - June 24 at 11:32 PM
streetinsider.com logoUltragenyx Pharma (RARE) Provides Regulatory Update on Burosumab Following Meeting with FDA - StreetInsider.com
www.streetinsider.com - June 23 at 9:28 AM
finance.yahoo.com logoUltragenyx Provides Regulatory Update on Burosumab (KRN23)
finance.yahoo.com - June 23 at 9:28 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc. (RARE) Expected to Post Quarterly Sales of $60,000.00
www.americanbankingnews.com - June 22 at 11:06 AM
americanbankingnews.com logoZacks: Brokerages Expect Ultragenyx Pharmaceutical Inc. (RARE) Will Announce Quarterly Sales of $60,000.00
www.americanbankingnews.com - June 22 at 11:06 AM
finance.yahoo.com logoOh, baby: How expanded newborn screening could change the face of health care
finance.yahoo.com - June 21 at 3:03 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc. (RARE) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - June 20 at 4:46 PM
americanbankingnews.com logo Brokerages Anticipate Ultragenyx Pharmaceutical Inc. (RARE) Will Post Earnings of -$1.73 Per Share
www.americanbankingnews.com - June 20 at 2:40 PM
finance.yahoo.com logoUltragenyx Pharmaceutical, Inc. – Value Analysis (NASDAQ:RARE) : June 16, 2017
finance.yahoo.com - June 16 at 8:28 PM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc. (RARE) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - June 16 at 9:40 AM
finance.yahoo.com logoUltragenyx Pharmaceutical, Inc. breached its 50 day moving average in a Bullish Manner : RARE-US : June 15, 2017
finance.yahoo.com - June 15 at 4:20 PM
globenewswire.com logoUltragenyx to Present at Goldman Sachs 38th Annual Global Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - June 8 at 8:46 AM
finance.yahoo.com logoUltragenyx to Present at Goldman Sachs 38th Annual Global Healthcare Conference
finance.yahoo.com - June 7 at 7:26 PM
finance.yahoo.com logoUltragenyx Pharmaceutical Inc. (RARE)
finance.yahoo.com - June 6 at 8:54 PM
americanbankingnews.com logoValuEngine Upgrades Ultragenyx Pharmaceutical Inc (RARE) to "Sell"
www.americanbankingnews.com - June 3 at 1:26 PM
finance.yahoo.com logoUltragenyx to Present at Jefferies Global Healthcare Conference
finance.yahoo.com - June 1 at 8:58 PM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) VP Theodore Alan Huizenga Sells 480 Shares
www.americanbankingnews.com - May 26 at 8:28 PM
americanbankingnews.com logoZacks: Brokerages Anticipate Ultragenyx Pharmaceutical Inc (RARE) to Post -$1.72 Earnings Per Share
www.americanbankingnews.com - May 25 at 10:28 AM
globenewswire.com logoUltragenyx Announces Recombinant Human Beta-Glucuronidase Biologics License ...
globenewswire.com - May 23 at 9:41 AM
streetinsider.com logoUltragenyx Pharma (RARE) Says Recombinant Human Beta-Glucuronidase BLA and MAA Filed and Accepted for Review; FDA Grants Priority Review Status
www.streetinsider.com - May 23 at 9:41 AM
finance.yahoo.com logoUltragenyx Announces Recombinant Human Beta-Glucuronidase Biologics License Application and Marketing Authorization Application Filed and Accepted for Review; FDA Grants Priority Review Status
finance.yahoo.com - May 23 at 9:41 AM
americanbankingnews.com logoUltragenyx Pharmaceutical Inc (RARE) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - May 22 at 7:56 AM
businesswire.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of Ultragenyx Pharmaceutical Inc. - Business Wire (press release)
www.businesswire.com - May 16 at 9:39 AM

Social

Chart

Ultragenyx Pharmaceutical (RARE) Chart for Sunday, August, 20, 2017

This page was last updated on 8/20/2017 by MarketBeat.com Staff